CAS-Ruiyi, a ZhenFund-backed angel investment project, has announced the successful completion of its A+ funding round, raising tens of millions of RMB. The round was led by Guoxin Fund. ZhenFund previously participated in CAS-Ruiyi’s angel round in 2021.
Founded as a spin-off from the Institute of Software at the Chinese Academy of Sciences, CAS-Ruiyi is an innovative medical technology company that translates cutting-edge neuroscience research into clinical applications. Leveraging achievements recognized by the National Science and Technology Progress Award, the company provides AI-driven solutions for the screening, diagnosis, treatment, and research of neurological disorders, addressing critical clinical challenges.
CAS-Ruiyi has established four major R&D and commercialization platforms, covering:
Quantitative assessment and diagnostic support for cognitive disorders
Quantitative assessment and diagnostic support for motor disorders
Eye movement function testing
Brain function intervention and training
With over ten specialized product pipelines, the company is actively building a "new infrastructure" for medical-engineering integration in brain science. Its core products have already secured six Class II National Medical Device Registration Certificates and are widely used in hundreds of leading medical institutions for clinical and research applications.
Committed to advancing clinical neuroscience research, CAS-Ruiyi collaborates with top-tier medical experts on dozens of high-impact clinical studies, with results published in leading medical journals such as Alzheimer’s & Dementia. The company has filed over 100 patents, with more than 50 granted, and has been recognized as a National High-Tech Enterprise, a Beijing "Specialized and New" SME, and a Zhongguancun High-Tech Enterprise.
Founder and Chairman Xiangmin Fan expressed gratitude for Guoxin Fund’s support, stating:
"We are honored to have the trust and backing of Guoxin Fund. CAS-Ruiyi will continue to expand R&D investment, deepen collaborations with top clinical teams, and accelerate the commercialization of innovative solutions. With strong support from both new and existing investors, recognition from our customers, and the dedication of our team, we are confident in delivering groundbreaking solutions for the prevention and intervention of neurological disorders—ultimately helping aging populations achieve longer, healthier lives."
The newly raised funds will be used primarily for product development, clinical trials, regulatory approvals, and market expansion.